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Abstract
Irritable Bowel Syndrome (IBS) represents a functional disorder of gastrointestinal tract without the presence of an 
anatomic defect, in which abdominal pain is relieved with defecation and is associated with altered bowel habits.
IBS includes a wide range of symptoms while its pathophysiology is very complicated. Recent studies indicate that the 
most important mechanisms include visceral sensitivity, abnormal gut motility and autonomous nervous system 
dysfunction. The interactions between these three mechanisms make bowel's function susceptible to many 
exogenous and endogenous factors like gastrointestinal flora, feeding and psychosocial factors. Recent data indicate 
that according to the above mechanisms, the influence of genetic factors and polymorphisms of human DNA in the 
development of IBS is equally important.
Introduction
IBS is a chronic continuous or remittent functional gas-
trointestinal disorder, characterized by abdominal pain,
bloating and bowel disturbance [1]. The Rome Commit-
tee for the Classification of Functional Gastrointestinal
Disorders has defined IBS on the basis of abdominal and
bowel symptoms that occur with sufficient frequency in
affected patients. More precisely, abdominal discomfort
or pain must be observed for at least 3 days every month,
for 3 months consecutive. The pain has two of the follow-
ing three features:
1) Relief by defecation
2) Onset associated with a change in the frequency of
stool
3) Onset associated with a change in the form of the
stool
At least 1/3 of the general population presents with
symptoms consistent with those of IBS. IBS seems to be
more frequent on low socioeconomic groups, which may
reflect unknown environmental factors, whereas these
appear to be a modest decline in prevalence with advanc-
ing age [2].
Clinically there are two categories of IBS. In the first
category, the prominent symptom is constipation,
whereas in the second, patients document diarrhea, as a
frequent manifestation of bowel dysfunction [3].
The etiology of IBS is most likely multifactorial. Several
environmental factors, psychosocial stressors, gut flora
alterations contribute to the pathophysiology of IBS,
along with abnormal gastrointestinal motility and secre-
tion and altered visceral perception. Today IBS is viewed
upon as a disorder of dysregulation of the brain-gut axis,
involving abnormal function in the enteric, autonomic
and/or central nervous systems [4].
The purpose of this review is to discuss the most
important pathophysiologic mechanisms that contribute
to the genesis of IBS, as well as to document the known
etiologic factors that have been correlated so far with the
clinical manifestation of IBS.
Pathophysiological Mechanisms
Visceral Hypersensitivity
The latest data indicate that the main mechanism induc-
ing abdominal pain is the visceral hypersensitivity [5].
The primary afferent neuron terminals of enteric nervous
system (ENS) which are localized in submucosal tunica of
gastrointestinal tract (Meissner plexus) and between
smooth muscle fibers (Auerbach plexus) transmit stimuli
to central nervous system (CNS) through sympathetic
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and parasympathetic autonomic nervous system (SANS
and PANS). SNS transmits stimuli which are recognized
as abdominal pain, whereas PNS transmits stimuli initiat-
ing a variety of reflexes. The pain stimuli through thala-
mus stimulate the cerebral cortex and permit the
recognition of visceral pain. On the other hand, for the
integration of visceral reflexes, the afferent stimuli
through hypothalamus stimulate efferent neural fibers
which through PNS stimulate or inhibit the contraction
of smooth muscle fibers and the secretion of enterocytes
in the gastrointestinal tract modifying the gut motility
and secretion [5].
It is known that visceral sensitivity is regulated in many
levels. Specifically this regulation is mediated at the level
of enteric mucosa and submucosa, the level of spinal
cord, the level of thalamus and the level of cerebral cor-
tex.
Visceral sensitivity at the level of enteric mucosa and 
submucosa
The presence of an injury in enteric mucosa leads to the
release of chemical mediators like K+, ATP and bradyki-
nin but also inflammatory mediators like prostaglandin
E2 (PGE2) [6]. These substances can directly stimulate the
afferent neuron terminals but also can induce the release
of algogenic substances (histamine, serotonin (5HT),
nerve growth factor (NGF) and prostaglandins). This cas-
cade leads to the amplification of the stimulus which rep-
resents the visceral pain [7].
There is particular interest about the interactions
between afferent neuron terminals and mast cells. The
release of substance P from the neuron terminals induces
the production and release of histamine and NGF from
mast cells. Histamine amplifies the release of substance P,
whereas NGF seems to be implicated in neuron termi-
nal's plasticity [8]. Recent data attribute the enhancement
of neural sensitivity for algogenic stimuli to increased
expression of sodium channels on primary afferent end-
ings [8].
Some of the inflammatory mediators, which are
released in enteric mucosa and submucosa seem to play a
more spesific role. Serotonin (5HT), is believed to stimu-
late the primary afferent neuron terminals. Recent stud-
ies on pseudoaffective (cardiovascular) reflex responses
to gut distension have suggested an action through a
5HT3 receptor subtype coupled to a sodium channel pres-
ent on primary afferent endings. 5HT3  antagonists
injected intravenously at low doses, potentiate visceral
analgesic effects in response to gut distension in different
rat models of abdominal pain [9].
It is known that bradykinin's signaling, influences vis-
ceral sensitivity in many ways [10]. Two bradykinin (BK)
receptor types have been identified. There are studies
that support that BK receptors are selectively upregulated
during processes that follow some types of intestinal tis-
sue injury and inflammation. Endogenous NGF released
from mast cells under various stimuli may increase the
primary afferent sensitivity to BK by upregulating BK
receptors. Studies in experimental animals have shown
that pharmacological agents which act as BK antagonists
relieve the abdominal pain induced by intraperitoneal
administration of acetic acid and urate crystals [11].
At the level of mucosa and submucosa, a variety of
mediators like adenosine, tachykinin, calcitonin gene-
related peptide (CGRP) and neurokinins participate in a
cascade of events. Many C afferent fibers have "silent
receptors" for neurokinins that can be sensitized by
inflammatory processes in peripheral tissues. Generally,
nerve remodeling occurring during inflammation can
trigger chronic hypersensitivity in the submucosa and
other intestinal structures [12]. These changes are com-
plex, time dependent and related to the nature of inflam-
mation. The acute phase of Nippostrongylus brasiliensis
infection is associated with a 2.5-fold increase in nerve
content of the tissues, chiefly as a result of axonal dilata-
tion. During the recovery phase when mast cell prolifera-
tion is established, the mean cross sectional area of the
nerve decreases but there is an increase in the diameter of
small fibers.
Visceral sensitivity at the level of spinal cord
The primary afferent neuron terminals stimulated by
algogenic stimuli release neurotransmitters, increasing
the efficancy of synaptic transmission between primary
afferents and dorsal horn neurons, a process, referred to
as central sensitization, which involves specific pre- and
postsynaptic receptors [11]. The mechanisms that under-
line central sensitization are not fully understood. In vivo
and in vitro pharmacological studies implicate coopera-
tion between substance P (SP) and N-methyl-D-aspartate
(NMDA) [6]. Recent studies support the idea that NMDA
receptors are implicated both at the level of spinal cord
and peripherally- related to the sensitization of primary
afferents. Substances that act as antagonists of these
receptors can selectively decrease visceral hypersensitiv-
ity. The interaction of SP receptors with protein kinace C
induces the phosphorylation of NMDA receptors, coun-
teracting the magnesium block and allowing NMDA
receptors to operate at a more negative potential [13]. In
this way SP seems to amplify the sensitivity of algogenic
signaling at this level as well. Recent data strongly suggest
that SP and neurokinin NK1 receptors are crucial for the
induction of central sensitization in rodents. However,
the failure of NK1receptor antagonists in clinical trials for
pain states indicates that another receptor may probably
fulfill this action in humans.
CGRP is present in most splanchnic afferents, and
CGRP immunoreactivity almost disappears from the gut
after either splanchnic nerve section or treatment withKarantanos et al. Gut Pathogens 2010, 2:3
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the sensory neurotoxin capsaicin. Moreover, CGRP
released at the spinal cord from central endings of pri-
mary afferents is important in the development of vis-
ceral hyperalgesia. Interestingly, peripherally released
CGRP may modify sensory inputs, causing changes in
blood flow, smooth muscle contractions, immune reac-
tion and mast cell degranulation. The intravenous admin-
istration of the CGRP1  antagonist (h)-CGRP-(8-37)
suppresses the abdominal cramps caused by intraperito-
neal administration of acetic acid in awake rats [14].
Many studies pointed out that μ and κ opioid agonists
lessen the nociceptive response to either peritoneal
administration of irritants or intestinal distension. It
seems also that κ agonists may act peripherally to prevent
visceral pain and are more active in inflammatory condi-
tions. It must be quoted that opioid receptors have been
identified on both smooth muscle fibers and primary
afferents localized in the gut [15]. These findings support
that opioids are implicated in IBS development in a more
complicated way and they influence not only the percep-
tion of the stimuli but stimuli per se as well.
Lastly, somatostatin and its receptors (SST1 and SST2)
have also been identified on spinal cord and are probably
related to the regulation of visceral pain, like GABAA and
a2 adrenergic receptors.
Visceral sensitivity at the level of cerebral cortex and 
subcortical areas
There are very little facts in literature about regulation of
visceral pain at the level of thalamus, limbic system and
cortex. It is believed that serotoninergic pathways, inhibit
neural impulses at the level of dorsal horn neurons. This
effect, mainly through the action of GABA neurons, reg-
ulates the conduction of nociceptive stimuli to CNS [16].
It seems also that the interactions between serotoninergic
pathways and limbic system are very important for the
sensation of visceral pain. The role of limbic system is not
clearly understood, but there are studies, which support
the correlation between visceral hypersensitivity syn-
dromes like IBS and emotional disorders like depression
and bipolar disorders. Negative emotional conditions like
fear and sorrow are related with abnormal sensory sensa-
tion and abdominal pain [17]. New studies with the use of
functional magnetic resonance correlate the presentation
of fearful expressions with stimulation of cortical and
subcortical areas, which increase the sensation of visceral
pain [18].
On the other side, stress is believed to modify the sen-
sation of colon and rectum distention both in controls
and IBS patients [19]. It seems that stress-induced release
of CRF from subthalamus increases the production of
mediators like histamine from mast cells. Interestingly,
sensory stimuli which reach CNS stimulate subthalamus
receptors leading to additional CRF release [20].
To summarise, the sensation of a visceral stimulus like
colon distention or the presence of an irritative substance
in the lumen is influenced by a variety of mediators at the
level of enteric mucosa, spinal cord, thalamus and cere-
bral cortex. Inflammatory and non-inflammatory agents
participate in the conduction and regulation of visceral
stimuli, whereas neuropeptides seem to be released from
inflammatory cells and neuron terminals.
Abnormal Gut Motility and Secretory Disorders
Gut motility
The enteric nervous system (ENS), which is located in
submucosa (Meisner plexus) and between smooth muscle
fibers (Auerbach plexus) regulates the neuromuscular
function of gastrointestinal (GI) tract. Sympathetic and
parasympathetic autonomic nervous system (SANS and
PANS) control the function of ENS, which is related to a
variety of mediators and receptors, like serotonin and its
receptors [21]. Serotonin is implicated in a variety of
reflexes, which regulate the gut motility and secretory
efficiency. These reflexes are integrated both at the level
of enteric mucosa, through ENS and at the levels of spinal
cord and subthalamus through PANS. It seems that
secreted serotonin stimulates afferent terminals leading
to a reflective gut peristalsis. In other words, the stimula-
tion of afferent terminals directly modifies the gut motil-
ity [22].
The stimulated primary afferent neuron terminals syn-
apse in the myenteric plexus (Auerbach plexus) with
ascending and descending inter-neurons, thus inducing
excitation and inhibition locally [23]. Ascending inter-
neurons activate excitatory motor neurons by releasing
substance P and acetylcholine (Ach) onto myocytes
resulting in circular muscle contraction. Descending cho-
linergic neurons stimulate inhibitory motor neurons
releasing nitric oxide (NO), vasoactive intestinal peptide
(VIP) and adenosine triphosphate (ATP) leading to circu-
lar muscle relaxation. The resulting peristaltic reflex is
largely responsible for the bolus movement from proxi-
mal to distal sites within GI tract [24].
Other studies evaluated the role of 5HT receptors in
the peristaltic reflex and demonstrated the intricate
involvement of CGRP. These investigators proposed that
the primary intrinsic afferent involved in this reflex is a
CGRP neuron activated by 5HT acting on 5HT4 receptors
[25]. In human jejunum, rat and guinea pig colon, the
5HT4 agonist tegaserod stimulated ascending contraction
and descending relaxation in vitro.
Activation of 5HT3 and 5HT4 receptors enhances gas-
trointestinal transit. Additionally, intrinsic afferents, uti-
lizing 5HT3 receptors, may be involved in a reflex circuit
within the gut that increases motility and intestinal secre-
tions [26]. Antagonism of the 5HT3 receptors with
ondansetron or alosetron delays colonic transit in healthyKarantanos et al. Gut Pathogens 2010, 2:3
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controls and in IBS patients with diarrhea as a predomi-
nant symptom [27].
New studies support that gut motility and defecation
are regulated by psychical, somatic and immune stress
[28]. The presence of a psychical and somatic stress like
dehydration leads to the increased expression of hor-
mone CRF in the paraventricular nucleus of hypothala-
mus [29]. The release of CRF from hypothalamic neurons
stimulates parasympathetic efferent pathways, which
increase gut motility. On the other hand, the intravenous
injection of CRF to humans increased colon motility, with
greater response to patients with IBS, which is an indica-
tion of the peripheral action of CRF [30].
2.2.2 Secretion
The regulation of intestinal secretions is comparable to
the regulation of gut motility. An initial stimulus stimu-
lates the afferent terminals, which integrate reflexes, cen-
trally through PANS and hypothalamus and peripherally
through ENS. The efferent neuron terminals, which stim-
ulate the intestinal secretion, are located in submucosa.
The intestinal secretions are both directly stimulated by
5HT4receptors located in postsynaptic endings and indi-
rectly by 5HT3 receptors, located at presynaptic endings.
5HT3 receptors are also located in the afferent neurons of
PANS. These neuron cells transfer the sensory stimuli to
hypothalamus for the integration of the reflex [31]. Sub-
stances, which are locally released from mast cells at the
mucosa level, are also responsible for the reflective intes-
tinal secretion. Besides serotonin, VIP and substance P
are also important.
Autonomic Nervous System Dysfunction
It is known that autonomic nervous system (ANS) regu-
lates visceral sensitivity and modulates and coordinates
GI motility and secretion [32]. New studies support that
sections of ANS are implicated in the immunological reg-
ulation and inflammatory reaction at the level of enteric
mucosa [33].
I t  i s  a l s o  r e p o r t e d  t h a t  m o s t  o f  I B S  s y m p t o m s  a r e
directly related to specific abnormalities of ANS. It seems
that the main characteristic of IBS patients is the
increased activity of SANS and the decreased activity of
PANS [34]. There are differences between patients with
diarrhea and constipation as predominant symptoms and
between men and women. It is believed that vagal dys-
function is associated with constipation as a predominant
symptom whereas adrenergic sympathetic dysfunction is
associated with diarrhea as a predominant symptom [35].
Other studies reported that IBS diarrhea-predominant
patients were shown to have cortisol hyper-responsive-
ness unlike that of constipation-predominant IBS
patients and controls [36]. Robert et al. [37] and Tillish et
al. [38], on the other hand, observed elevated sympathetic
dominance and vagal withdrawal during non-REM and
REM sleep in diarrhea-predominant IBS patients, but not
in those with an alternating type of IBS. However, consti-
pation-predominant IBS patients could not be distin-
guished from diarrhea-predominant IBS patients or
alternating type IBS with regard to autonomic nervous
system. It is reported that there might be a continuum of
autonomic dysfunction among these symptom-specific
subgroups [39].
Concerning sex-specific alterations in autonomic func-
tion among IBS patients, it is believed that there are dif-
ferences in visceral sensitivity both at the level of mucosa,
and at the level of central pain sensation [40]. Recent evi-
dence has confirmed that sex differences exist among IBS
patients in term of colonic transit response to pharmaco-
logical treatment [41]. These observations may justify the
different IBS incidence between male and female. It is
also found that male IBS patients had significantly higher
sympathovagal balance than healthy male controls,
whereas no differences were noted between IBS females
and female controls. However, differences in autonomic
nervous system responses to specific stimuli may also
play a role in producing sex-based variations in IBS
symptom patterns and in differential responses to some
pharmacological agents [42].
Increased SNS activity and decreased PNS activity are
the most frequent noted signs in IBS patients. We often
observed cutaneous hyperalgia in IBS patients. Mayer et
al. [43] reported that patients with IBS also exhibited a
number of extraintestinal manifestations such as
migraine headache, back pain, heartburn, dyspareunia
and muscle pain, consistent with the central hyperalgesic
mechanism.
Etiologic Factors
Small Intestine Bacterial Overgrowth Syndrome
About 65-84% of IBS patients present with small intestine
bacterial overgrowth, that is, presence of more than 105
cfu/ml of bacteria, resembles the bacterial composition of
the colon, in the proximal small bowel [44]. The coloniza-
tion of gastrointestinal tract differs according to the type
of bacteria. Particularly, bacteria from the upper respira-
tory tract and anaerobic bacteria from oral cavity via the
slobber swallowing, colonize the upper gastrointestinal
tract with a density of < 105 cfu/ml. The stomach is colo-
nized by bacteria with a density of < 103 cfu/ml because
the acidic pH does not permit the colonization and prolif-
era tion of bacteria coming from the oral ca vity . In the
small intestine, there is a progressive colonization of
gram positive aerobic and facultative anaerobic bacteria,
like staphylococcus, streptococcus, lactobacillus and
some types of fungi. The presence of gram-negative and
anaerobic bacteria in the proximal jejunum is abnormal.
Strains of Prevotella disiens and P. divia are recognized in
the small intestine. Normally, small intestinal microfloraKarantanos et al. Gut Pathogens 2010, 2:3
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i s  b e l i e v e d  t o  b e  e x o g e n o u s  a n d  n o t  e n d o g e n o u s  [ 4 5 ] .
Anaerobic strains and mainly Bacteroides fragilis are usu-
ally restricted in the distal jejunum and large intestine
(Table 1). The ecology of small intestine's content is con-
stant due to normal bowel motility, acidic pH and IgA
secretion from small intestine mucosa.
It has been documented that in pathological cases of
small intestine bacterial overgrowth, there are excessive
bacterial counts in the proximal small bowel, commonly
with bacterial species including Streptococci, Bacteroides,
Escherichia, and Lactobacilli.
Bacterial overgrowth implies abnormal colonization of
the upper gastrointestinal tract, arising from failure of
specific defense mechanisms restricting colonization
under physiological conditions. These defense mecha-
nisms are the gastric acid barrier and the intestinal clear-
ance.  H. pylori induced-gastritis is the main cause of
acquired failure of the gastric acid barrier. Failure of
intestinal clearance may come as a result of impaired
intestinal persistalsis, in case of myopathic, neuropathic,
autoimmune, infectious, metabolic, endocrine or neo-
plastic diseases. Anatomical abnormalities that alter
luminal flow may as well cause failure of intestinal clear-
ance. This may be the result of gastrointestinal surgery,
intestinal diverticula, or fistula [46].
The bacterial content of oral cavity, host's general con-
dition, immunological disorders and bad nutrition play
important role in the development of bacterial over-
growth syndrome.
Post Infectious Irritable Bowel Syndrome
Post infectious IBS (PI IBS) represents a subtype of IBS. It
affects 6-17% of IBS patients, who had undergone a previ-
ous episode of infectious gastroenteritis [47]. While most
patients rapidly recover from bacterial gastroenteritis,
about a quarter show persistent disturbance of bowel
habit at 6 months and most commonly increased stool
frequency. A smaller number develop persistent symp-
toms that meet the Rome III criteria. Clinical features
include bloating, loose and watery stools, urgency for
defacation and the passage of mucus per rectum [48].
There are indications that an episode of acute gastroen-
teritis is capable to induce small intestine sensitization
and symptoms of IBS, only if there are other factors
mainly psychosocial, which can stimulate through psy-
chical, neuronal and endocrinal mechanisms, the pres-
ence of mast cells and other inflammatory cells in the
gastrointestinal tract [49].
PI IBS has been reported after Campylobacter, Salmo-
nella and Shigella  infections [50]. Those patients, who
later on develop IBS, show increased numbers of entero-
chromaffin (EC) cells and lymphocyte cell counts at 3
months compared to those who do not develop IBS.
Interleukin-1β (IL-1β) mRNA levels are increased in the
mucosa of those who develop PI IBS and show also
increased gut permeability. Recent studies suggest an
increase in peripheral blood mononuclear cell cytokine
production in unselected patients, an abnormality that
may be ameliorated by probiotic treatment. Recovery
from PI IBS may be slow, with approximately 50% of
patients manifesting symptoms at 5 years.
One measure to estimate the probability to develop PI
IBS, is the duration of the initial diarrheal illness. Diar-
rhea lasting more that 3 weeks gives a relative risk of 11.4
compared with diarrhea lasting less than 7 days. Changes
in the epithelium, during the healing process, are also
predictive of the development of PI IBS. Age above 60
gives a protective effect. It seems that older subjects have
fewer immunocytes in their rectal mucosa and may be
less reactive to infection. Depression and the presence of
adverse life events double the relative risk of persistent
symptoms [51].
Diet
Acute hypersensitivity reactions are rare causes of IBS.
Patients often present with atopic conditions, such as
eczema, asthma, angioedema, while they respond well to
elimination diets [52]. Those hypersensitivity reactions
are mediated by degranulation of mast cells.
The degranulation of mast cells leads to the production
of local and systemic mediators, such as leucotriens LTC4
and histamine, which act upon adjacent smooth muscle
cells and nerve endings.
Lactose intolerance, as well as intolerance to sorbitol or
fructose, has been implicated in IBS. It is likely that the
specific enzyme deficiency is not the cause of IBS, but
that the hypersensitive guts of patients with IBS show
exaggerated responses to the gaseous and fluid distention
caused by incomplete absorption of carbohydrate.
Table 1: Microbiologic Ecology of the Normal Human 
Intestinal Tract
Oral cavity Staphylococcus epidermidis
Streptococcus mitis
Streptococcus salivarius
Streptococcus mutans
Lactobacillus spp.
Stomach Helicobacter pylori
Lactobacillus spp.
Small bowel Bacteroides fragilis
Prevotella disiens
Prevotella divia
Enterococcus spp
Lactobacillus spp.
Colon Bacteroides fragilis
Enterococcus faecalis
Bifidobacterium spp
Peptostreptococcus spp
Lactobacillus spp.
Clostridium spp.
Escherichia coliKarantanos et al. Gut Pathogens 2010, 2:3
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Psychical Factors
The correlation between emotion and gut motility has
now been established. Many physiology studies have
shown that anger is closely associated with enhanced
contractile activity in the sigmoid-rectum area, whereas
reduced motility is documented in case of fear. Anxiety
can induce rapid small bowel transit and enhanced stool
frequency. Moreover, depression is associated with
delayed small bowel and colonic transit.
The effects of emotion on gastrointestinal function are
mediated by the autonomic nervous system. The normal
physiologic response to acute stress involves the linked
activation of the hypothalamo-pituitary axis and the sym-
pathetic nervous system. The brain may influence the
transmission of nociceptive information from the gut and
the activation of visceral reflexes through descending
inhibitory and excitatory pathways that terminate within
the dorsal horn at the secondary sensory neuron.
Common characteristics of IBS patients are the patho-
logic gradation of visceral perception, the endogenous
pain facilitation and the reduced threshold for pain.
Abuse history is common in their past, exaggerated con-
scientiousness, perfectionism and neuroticism have been
detected among their personality features [53].
Genetic Predisposing
There is growing evidence regarding the genetic contri-
bution in the syndrome [54]. The genetic base of IBS is
supported by the fact that the syndrome has characteris-
tics similar to multifactorial and multigenic disorders,
such as the different incidence in different geographic
areas [55].
The evaluation of genetic influence is based on familial
aggregation, twin studies and genetic epidemiological
studies focusing on gene polymorphisms [55].
Familial Aggregation
Although the family clustering of IBS has been noticed in
medical practice for several years, Whorwell et al. [56]
found that 33% of patients with IBS reported a family his-
tory of IBS compared with only 2% of the control group.
Newer studies showed relation between having a first
degree relative with bowel problems and presenting with
IBS, concluding that these results may represent exposure
to similar environmental factors [57], although some lim-
itations of these studies included the fact that only
abdominal symptoms in first degree relatives were
assessed and that the IBS diagnosis was not confirmed by
a specialist.
Twin Studies
An Australian study by Morris-Yates et al. [58], showed a
higher concordance rate for IBS in monozygotic twins
than in dizygotic twins (33.3% vs 13.3%). Interestingly, an
American study conducted in 2001 showed that the con-
cordance rate in monozygotic twins was twice as high as
that in dizygotic twins (17.2% vs 8.4%) [59]. However, the
number of dizygotic twins with IBS who have mothers
with IBS was greater than the number of dizygotic twins
with IBS who have co-twins with IBS; data also showed
that having a mother or a father with IBS are both inde-
pendent predictors of irritable bowel status and are stron-
ger predictors than having a twin with IBS. These results
support also that social learning has an important influ-
ence [59]. However a Norwegian study published in 2006
showed a concordance for IBS significantly greater in
monozygotic than in dizygotic twins. The same study,
showed, that low birth weight also influences significantly
the development of IBS [60]. Finally, another twin study
published in 2007 concluded that the genetic factors are
involved in IBS, possibly by the hereditability of anxiety
and depression [61].
Gene Polymorphisms
The delineation of the regulation of the fut-brain axis at
the level of sensation and motility by mediators like 5HT,
cholecystokinin (CCK) and substance P, has lead to the
investigation of a variety of polymorphisms. Gene poly-
morphisms involve the serotonergic and adrenergic sys-
tems and genes encoding proteins with
immunomodulatory and/or neuromodulatory features
[62]. One candidate gene is the serotonin transporter
gene (SERT). The serotonin transporter protein is
responsible for reuptake of serotonin from the synaptic
cleft. Within this gene, there is a 44 bp insertion/deletion
of repeat elements in the promoter region. This polymor-
phism results in a long (l), and a sort (s) allele. The s allele
is associated with lower transcriptional efficiency and
therefore lower serotonin transporter expression, and
decreased cellular uptake of serotonin. Recent studies
showed relation between the presence of l/l genotype and
IBS with constipation as the predominant symptom and
decreased response to tegaserod [63]. Other studies
revealed that the presence of the s/s genotype is related to
IBS with diarrhea as the predominant symptom, particu-
larly in women [63]. A recent Indian study showed that
the presence of the s/s genotype is related to IBS with
constipation as the predominant symptom [64].
Association studies of polymorphisms in genes encod-
ing CCK [65], adrenergic receptors [66] and cytokines
like TNF-a and IL-10 investigating the relation between
IBS and inflammation [67] have been also reported.
Finally, IBS is a multifactorial functional disorder which
is related to genetic, environmental and psychological
factors. Due to the important influence of environmental
and psychological factors in the development of IBS
many studies are required to confirm the genetic base of
the syndrome.Karantanos et al. Gut Pathogens 2010, 2:3
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